This study is testing a new way to understand the stage and outlook (prognosis) for people with malignant pleural mesothelioma. Currently, it's hard to know the cancer's stage before surgery or treatment. This research uses tissue samples from your diagnostic biopsy to study specific characteristics with tests like the MPT Test and CLDN15/VIM Test. The goal is to see if these tests can help doctors better classify your cancer stage and predict your prognosis before treatment. We are looking for adults aged 18 or older who have been diagnosed with malignant pleural mesothelioma and are having a diagnostic pleural biopsy, pleuroscopy, or VATS resection. Success for this study means validating a new method for predicting prognosis, measured over 4 years. The current recruitment status is unclear.

Study design

This is an interventional study planning to enroll 240 participants. It is not specified if it is randomized or blinded.

What's involved

If you join, doctors will collect pleural tissue samples during your routine diagnostic biopsy. This tissue will be stored and studied to test the new method.

Compensation

Not stated in the trial record.

Follow-up

The primary goal of the study is measured at 4 years, which suggests a follow-up period of at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.